Roche (RHHBY) announced positive results from an early-stage study evaluating one of its recently acquired obesity drug candidates, CT-388. Over 24 weeks, patients who received this once-weekly, subcutaneously- injected drug achieved a mean placebo-adjusted weight loss of 18.8%. Per management, the above results were ‘clinically meaningful and statistically significant’ when compared with placebo. Roche also provided an insight into this data. While all patients who received CT-388 achieved more than a weig ...